1-acetoxy-4-chloro-but-2-yne | 34452-25-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-acetoxy-4-chloro-but-2-yne
• 英文别名: 4-acetoxy-1-chloro-2-butyne；1-Acetoxy-4-chlor-but-2-in；ω-chlorobutyn-2-yl acetate；4-chlorobut-2-ynyl acetate；acetic acid-(4-chloro-but-2-ynyl ester)；4-chlorobutyl-2-yne-1-yl acetate；4-chlorobut-2-yn-1-yl acetate；1-Acetoxy-4-chlor-butin-2；4-Chlor-1-acetoxy-butin-2；Essigsaeure-(4-chlor-but-2-inylester)；4-chloro-2-butynyl acetate
• CAS: 34452-25-0
• 化学式: C₆H₇ClO₂
• mdl: MFCD19232043
• 分子量: 146.573
• InChiKey: HRWWMYRTNPCIQO-UHFFFAOYSA-N

物化性质

• 沸点：
  98-100 °C(Press: 14 Torr)
• 密度：
  1.1257 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-acetoxy-4-chloro-but-2-yne 在 palladium diacetate 、 三苯基锑 、 sodium hydride 、 溶剂黄146 、 三乙胺 、 三苯基膦 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 以 氘代苯 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 162.0h， 生成 dimethyl 3-acetoxymethyl-4-ethenyl-3-cyclopentene-1,1-dicarboxylate
  参考文献：
  名称：

  钯催化 2-Bromo-1,6-二烯和-1,6-烯炔双环化成 5-元环-退火乙烯基环丙烷衍生物

  摘要：

  钯催化的 2-溴-1,6-二烯 6 与溴烯基部分上的乙酰氧基甲基取代基的环化不仅产生预期的 1-乙酰氧基甲基-1,3-二烯 40，而且产生双环乙烯基环丙烷 35， 1,3-二烯 36 和三烯 37（树枝状烯）。所有这些化合物均由 2-溴-1,6-二烯的初始 5-exo-trig 环化产生。By proper choice of the reaction conditions (ligand, base, allylic leaving group) each of these compounds could be formed selectively. 少量 (3–5%) 的异构化 1-乙酰氧基甲基-1,3-二烯 38 和 6-内产物 39 也被分离出来。由于烯基部分（化合物27）上的乙酰氧基甲基取代基，仅形成1,4-二烯44。在三键上具有甲氧基羰基氧基亚甲基取代基的相关 1,6-烯炔 57

  DOI：

  10.1002/(sici)1099-0690(199906)1999:6<1333::aid-ejoc1333>3.0.co;2-g
• 作为产物：
  描述：

  4-acetoxy-2-butyn-1-ol 在 吡啶 、 氯化亚砜 作用下， 以 苯 为溶剂， 以89%的产率得到1-acetoxy-4-chloro-but-2-yne
  参考文献：
  名称：

  Structural Properties of Dibenzosuberanylpiperazine Derivatives for Efficient Reversal of Chloroquine Resistance in Plasmodium chabaudi

  摘要：

  For the purpose of developing chemosensitizers to reverse chloroquine (CQ) resistance in Plasmodium chabaudi in vivo, dibenzosuberanylpiperazine (1-(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)piperazine) (DSP) and its piperazin-1-yl derivatives were synthesized systematically. DSP hydrochloride (3) was obtained from the reaction of dibenzosuberanyl chloride with piperazine in the presence of 1,8-diazabicyclo[5,4,0]-7-undecene (DBU). To understand the relationship between the substituent patterns of DSP derivatives and their biological activities, 13 hydroxyalkyl or hydroxyalkenyl derivatives were synthesized by an attack of the piperazine secondary amine of 3 on commercially available epoxides in the presence of triethylamine or DBU, and three alkyl or alkynyl derivatives were synthesized by the reactions of 3 with the corresponding organic chlorides in the presence of DBU. In both reactions, the yield was a maximum of 90%. The biological activities of the synthesized compounds were evaluated on the basis of two values: antimalarial activity and reversal activity. The values of antimalarial activities by single administration of 17 test compounds were not effective, being in the range 67-152% on day 4 after infection of Plasmodium chabaudi to mice except for the administration of 3-(dibenzosuberanylpiperazin-1-yl)-1-butene (29, 22%). On the other hand, administration of the seven test compounds (50 mg/kg dose) combined with CQ (3-4 mg/kg) gave high reversal activities, namely, low values (0% on day 4). The effective test compounds were those obtained by introducing the following substituents: 2-hydroxybutyl (24), 2-hydroxyhexen-5-yl (27), 2-hydroxybuten-3-yl (28a), 2-substituted 1-hydroxybuten-3-yl (28b), 4-acetoxybutyn-2-yl (30), 4-hydroxybutyn-2-yl (31), and 3-substituted buten-1-yl (29), which correspond to the nonbulky groups of hydroxyalkyl (C4), hydroxyalkenyl (C4-C6), hydroxyalkynyl (C4), or alkenyl (C4). These results may lead to the development of an approach to developing clinically applicable chemosensitizers for drug-resistant malaria.

  DOI：

  10.1021/jm020379v

文献信息

• Studies of bioactive heterocycles: facile thio-Claisen rearrangement of propargylthio[1]benzopyran-2-ones
  作者：K.C Majumdar、S.K Ghosh

  DOI：10.1016/s0040-4039(02)00195-8

  日期：2002.3

  Hitherto unreported 2H-thiopyrano[3,2-c][1]benzopyran-5-ones 6a–f are synthesized regioselectively in 79–85% yields by the thio-Claisen rearrangement of 4-propargylthio[1]benzopyran-2-ones 5a–f. The substrates 5a–f are synthesized by alkylation of hitherto unreported 4-mercaptocoumarins.

  迄今为止，未报告的2 H-硫代吡喃并[3,2- c ] [1]苯并吡喃-5-酮6a – f通过4-炔丙基硫代[1]苯并吡喃-2-的硫代克莱森重排以79–85％的产率进行区域选择性合成。那些5A - ˚F。通过迄今未报道的4-巯基香豆素的烷基化来合成底物5a - f。
• Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such
  申请人：Nique Francois

  公开号：US20100063120A1

  公开（公告）日：2010-03-11

  Compounds of formula (I): wherein X is O or S, R 1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R 2 is H. alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R 3 and R 4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl; or R 3 and R 4 form an, optionally aromatic or heterocyclic, optionally substituted ring, R 5 is H, halogen, trifluoromethyl, —CN, or —NO2; not all of R 3 , R 4 , and R 5 being H, R 6 and R 9 are H, halogen, OH; alkyl. hydroxyalkyl, alkoxyl, thioalkyl, haloalkyl, alkenyl, or alkynyl; R 7 and R 8 are H, halogen, OH, SH; alkoxyl or alkylthio optionally substituted by OH and/or halogen; one of R 7 and R 8 not being H or halogen; or one of R 7 and R 8 is a pharmaceutically acceptable ester or thioester grouping, or R 6 is C 1-3 -alkyl or, together with either R 1 or R 2 , represents C 1-3 alkylene or alkenylene linking group, optionally substituted by methyl, trifluoromethyl, OH, or halogen, and pharmaceutically acceptable salts and esters thereof, are useful as selective androgen modulators.

  式(I)的化合物：其中X为O或S，R1为酰基，醛基，环烷基，或可选择地取代的烷基，烯基或炔基，R2为H，烷基，羟基烷基，卤代烷基，烯基或炔基；取代烷基；烷基羰基；R3和R4为H，卤素，烷基，烯基，炔基，烷氧基，烷硫基，羟基烷基，卤代烷基，卤代烯基，或卤代炔基；或R3和R4形成一个，可选择的芳香或杂环，可选择地取代的环，R5为H，卤素，三氟甲基，-CN，或-NO2；R3，R4和R5中不全为H，R6和R9为H，卤素，羟基；烷基，羟基烷基，烷氧基，硫代烷基，卤代烷基，烯基，或炔基；R7和R8为H，卤素，羟基，硫氢基；烷氧基或烷硫基，可选择地由羟基和/或卤素取代；R7和R8中的一个不为H或卤素；或R7和R8中的一个为药用可接受的酯或硫酯基团，或R6为C1-3-烷基或，与R1或R2中的任一者一起，代表C1-3烷基或烯基链连接基，可选择地由甲基，三氟甲基，羟基，或卤素取代，以及其药用可接受的盐和酯，可用作选择性雄激素调节剂。
• PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE
  申请人：JIANGSU HENGRUI MEDICINE CO., LTD.

  公开号：US20200157111A1

  公开（公告）日：2020-05-21

  The present invention relates to a piperazine heteroaryl derivative, a preparation method therefor and the use of same in medicine. In particular, the present invention relates to the piperazine heteroaryl derivative as shown in the general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and the use of same as a capsid protein inhibitor, in particular in the prevention and/or treatment of diseases such as hepatitis B, influenza, herpes, AIDS, etc. The definitions of each group in the general formula (I) are the same as those defined in the description.

  本发明涉及一种哌嗪杂环芳基衍生物，其制备方法以及在医学上的用途。具体来说，本发明涉及如通用式（I）所示的哌嗪杂环芳基衍生物，其制备方法，包括该衍生物的药物组合物，以及将其用作壳蛋白抑制剂，特别是在预防和/或治疗乙型肝炎、流感、疱疹、艾滋病等疾病方面。通用式（I）中每个基团的定义与描述中定义的相同。
• [1]Benzopyrano[4,3-c]pyrazoles by intramolecular nitrile imine addition to acetylenes
  作者：Dietmar Janietz、Wolf-Dieter Rudorf

  DOI：10.1016/s0040-4020(01)80030-2

  日期：1989.1

  propargylester or 1-acetoxy-4-chloro-but-2-yne. The aldehydes are converted into the hydrazones 2 by reaction with p-toluenesulfonylhydrazide. Dehydrogenation of with lead tetraacetate yields 2,4-dihydro[1]benzopyrano[4,3-c]pyrazoles . In one case the acylated by-product has been formed.

  通过用对甲苯磺酸炔丙基酯或1-乙酰氧基-4-氯丁-2-炔将相应的水杨醛烷基化而获得2-炔氧基-苯甲醛。通过与对甲苯磺酰基酰肼反应，将醛转化为2。用四乙酸铅脱氢，得到2，4-二氢[1]苯并吡喃并[4，3-c]吡唑。在一种情况下，已经形成酰化副产物。
• IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH
  申请人：NIQUE Francois

  公开号：US20100210699A1

  公开（公告）日：2010-08-19

  Compounds of formula (I): wherein X is O or S, R 1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R 2 is H, alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R 3 and R 4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl; or R 3 and R 4 form an, optionally aromatic or heterocyclic, optionally substituted ring, R 5 is H, halogen, trifluoromethyl, —CN, or —NO 2 ; not all of R 3 , R 4 , and R 5 being H, R 6 and R 9 are H, halogen, OH; alkyl, hydroxyalkyl, alkoxyl, thioalkyl, haloalkyl, alkenyl, or alkynyl; R 7 and R 8 are H, halogen, OH, SH; alkoxyl or alkylthio optionally substituted by OH and/or halogen; one of R 7 and R 8 not being H or halogen; or one of R 7 and R 8 is a pharmaceutically acceptable ester or thioester grouping, or R 6 is C 1-3 -alkyl or, together with either R 1 or R 2 , represents C 1-3 alkylene or alkenylene linking group, optionally substituted by methyl, trifluoromethyl, OH, or halogen, and pharmaceutically acceptable salts and esters thereof, are useful as selective androgen modulators.

  化合物式（I）：其中X为O或S，R1为酰基，醛基，环烷基，可选取代的烷基，烯基或炔基，R2为H，烷基，羟基烷基，卤代烷基，烯基或炔基；取代烷基；烷基羰基；R3和R4为H，卤素，烷基，烯基，炔基，烷氧基，烷硫基，羟基烷基，卤代烷基，卤代烯基或卤代炔基；或R3和R4形成一个可选的芳香或杂环，可选取代的环，R5为H，卤素，三氟甲基，—CN或—NO2；R3，R4和R5不全为H，R6和R9为H，卤素，OH；烷基，羟基烷基，烷氧基，硫代烷基，卤代烷基，烯基或炔基；R7和R8为H，卤素，OH，SH；烷氧基或烷硫基，可选取代为OH和/或卤素；R7和R8中的一个不为H或卤素；或R7和R8中的一个是药物可接受的酯或硫酯基团，或R6为C1-3烷基或与R1或R2中的一个共同表示C1-3烷基或烯基链连接基团，可选取代为甲基，三氟甲基，OH或卤素，以及其药物可接受的盐和酯，用作选择性雄激素调节剂。